• Something wrong with this record ?

Neurofilament Light Chain Levels Are Associated with Disease Activity Determined by No Evident Disease Activity in Multiple Sclerosis Patients

J. Szilasiová, J. Rosenberger, M. Fedičová, P. Mikula, P. Urban, Z. Gdovinová, M. Vitková, J. Hanes, E. Stevens

. 2021 ; 84 (4) : 272-279. [pub] 20210525

Language English Country Switzerland

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22012558

INTRODUCTION: There is a need for blood biomarkers of disease activity in multiple sclerosis (MS). The aim of the study was to assess the relationship between plasma neurofilament light chain (pNfL) and disease activity as defined by the concept three-domain no evident disease activity (NEDA-3). METHODS: Levels of pNfL (SIMOA) were examined in 159 MS patients and analyzed in relationship to NEDA-3 status (absence of relapse, disability score worsening, and brain magnetic resonance activity) during the last 12 months. The accuracy of the proposed model was evaluated by calculating the area under the receiver operating characteristics (ROC) curve. From the pNfL cutoff, we evaluated the NEDA-NfL status (no relapse, no Expanded Disability Status Scale [EDSS] worsening, and pNfL below the cutoff value). RESULTS: Levels of pNfL were significantly higher in MS patients than in healthy controls (p < 0.001). From a total of 159 patients, 80 (50.3%) achieved NEDA-3 status, while 79 (49.7%) patients showed evident disease activity (EDA) status. pNfL were significantly lower in the NEDA-3 group than in the EDA group (pNfL mean 7.06 pg/mL [standard deviation (SD) 2.37] vs. pNfL mean 13.04 pg/mL [SD 7.07]) (p < 0.001). ROC analysis showed that pNfL predicts NEDA-3 status (sensitivity and specificity were 80.5 and 72.7%, respectively, p < 0.001), and NEDA-NfL predicts NEDA-3 status (sensitivity and specificity were 97.1 and 82.9%, respectively, p < 0.001). CONCLUSION: The results show that pNfL levels are a useful biomarker of disease activity determined by NEDA status in patients with MS and could be an alternative to brain magnetic resonance investigation.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012558
003      
CZ-PrNML
005      
20230117095507.0
007      
ta
008      
220425s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000515806 $2 doi
035    __
$a (PubMed)34034261
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Szilasiová, Jarmila $u Department of Neurology, Pavol Jozef Šafárik University, Košice, Slovakia
245    10
$a Neurofilament Light Chain Levels Are Associated with Disease Activity Determined by No Evident Disease Activity in Multiple Sclerosis Patients / $c J. Szilasiová, J. Rosenberger, M. Fedičová, P. Mikula, P. Urban, Z. Gdovinová, M. Vitková, J. Hanes, E. Stevens
520    9_
$a INTRODUCTION: There is a need for blood biomarkers of disease activity in multiple sclerosis (MS). The aim of the study was to assess the relationship between plasma neurofilament light chain (pNfL) and disease activity as defined by the concept three-domain no evident disease activity (NEDA-3). METHODS: Levels of pNfL (SIMOA) were examined in 159 MS patients and analyzed in relationship to NEDA-3 status (absence of relapse, disability score worsening, and brain magnetic resonance activity) during the last 12 months. The accuracy of the proposed model was evaluated by calculating the area under the receiver operating characteristics (ROC) curve. From the pNfL cutoff, we evaluated the NEDA-NfL status (no relapse, no Expanded Disability Status Scale [EDSS] worsening, and pNfL below the cutoff value). RESULTS: Levels of pNfL were significantly higher in MS patients than in healthy controls (p < 0.001). From a total of 159 patients, 80 (50.3%) achieved NEDA-3 status, while 79 (49.7%) patients showed evident disease activity (EDA) status. pNfL were significantly lower in the NEDA-3 group than in the EDA group (pNfL mean 7.06 pg/mL [standard deviation (SD) 2.37] vs. pNfL mean 13.04 pg/mL [SD 7.07]) (p < 0.001). ROC analysis showed that pNfL predicts NEDA-3 status (sensitivity and specificity were 80.5 and 72.7%, respectively, p < 0.001), and NEDA-NfL predicts NEDA-3 status (sensitivity and specificity were 97.1 and 82.9%, respectively, p < 0.001). CONCLUSION: The results show that pNfL levels are a useful biomarker of disease activity determined by NEDA status in patients with MS and could be an alternative to brain magnetic resonance investigation.
650    _2
$a biologické markery $7 D015415
650    _2
$a mozek $7 D001921
650    _2
$a lidé $7 D006801
650    _2
$a intermediární filamenta $7 D007382
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    12
$a roztroušená skleróza $x diagnostické zobrazování $7 D009103
650    12
$a relabující-remitující roztroušená skleróza $7 D020529
650    _2
$a ROC křivka $7 D012372
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Rosenberger, Jaroslav $u Department of Health Psychology and Methodology of Research, II. Internal clinic, Pavol Jozef Šafárik University, Košice, Slovakia $u Olomouc University Social Health Institute, University Palacky, Olomouc, Czechia
700    1_
$a Fedičová, Miriam $u Department of Neurology, University Hospital L. Pasteur Košice, Košice, Slovakia
700    1_
$a Mikula, Pavol, $u Department of Social and Behavioral Medicine, Pavol Jozef Šafárik University, Košice, Slovakia $d 1988- $7 xx0280701
700    1_
$a Urban, Peter $u Department of Medical and Clinical Biochemistry, Pavol Jozef Šafárik University, Košice, Slovakia
700    1_
$a Gdovinová, Zuzana $u Department of Neurology, Pavol Jozef Šafárik University, Košice, Slovakia
700    1_
$a Vitková, Marianna $u Department of Neurology, Pavol Jozef Šafárik University, Košice, Slovakia
700    1_
$a Hanes, Jozef $u Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia $u AXON Neuroscience R&D Services SE, Bratislava, Slovakia
700    1_
$a Stevens, Eva $u AXON Neuroscience R&D Services SE, Bratislava, Slovakia
773    0_
$w MED00001655 $t European neurology $x 1421-9913 $g Roč. 84, č. 4 (2021), s. 272-279
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34034261 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20230117095504 $b ABA008
999    __
$a ok $b bmc $g 1789957 $s 1163759
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 84 $c 4 $d 272-279 $e 20210525 $i 1421-9913 $m European neurology $n Eur Neurol $x MED00001655
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Archiving options